MEI Pharma, Inc.
11455 El Camino Real, Suite 250
San Diego
California
92130
United States
Tel: (858) 369-7100
Website: https://www.meipharma.com/
Email: HR@meipharma.com
About MEI Pharma, Inc.
MEI Pharma is clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer.
MEI Pharma's portfolio of drug candidates includes multiple clinical-stage assets, including zandelisib, currently in ongoing clinical studies intended to support marketing applications with the U.S. Food and Drug Administration and other regulatory authorities globally. Each of MEI Pharma's pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors that we believe: (1) have the potential to be best-in-class, (2) address unmet medical needs and (3) deliver improved outcomes to patients either as standalone treatments or in combination with other therapeutic options. MEI is headquartered in San Diego, CA.
Stock Symbol:
MEIP
345 articles with MEI Pharma, Inc.
-
MEI Pharma Announces Adjournment of Annual Meeting of Stockholders
12/6/2022
MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, announced today that its annual meeting of stockholders has been adjourned to January 5, 2023, at 9:00 a.m. Pacific Time.
-
MEI Pharma, Inc. will have a strategic realignment that would see at least 30% of its workforce laid off and a pivot towards two of its earlier clinical-stage assets.
-
MEI Pharma Initiates Strategic Realignment
12/5/2022
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it plans to initiate a realignment of its clinical development efforts following the discontinuation of global development outside Japan of its PI3K delta inhibitor, zandelisib.
-
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
12/5/2022
MEI Pharma, Inc. (Nasdaq: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced that after receiving the most recent guidance from a late November meeting with the U.S. Food and Drug Administration (FDA), the companies are discontinuing global development of zandelisib outside of Japan for B-cell malignancies.
-
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
11/18/2022
Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) and MEI Pharma, Inc. (NASDAQ: MEIP) today announced topline data from the Phase 2 MIRAGE study evaluating zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor, in patients with indolent B-cell Non-Hodgkin’s Lymphoma (iB-NHL) without small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), and Waldenström's macroglobulinemia (WM) in Japan.
-
MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights
11/14/2022
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported results for the quarter ended September 30, 2022, and highlighted recent corporate events.
-
MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022
11/3/2022
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced that three abstracts highlighting data and information from the clinical development program evaluating the intermittent dosing of zandelisib, an investigational phosphatidylinositol 3-kinase delta inhibitor for the treatment of B-cell malignancies, will be presented at the upcoming American Society of Hematology 2022 Annual Meeting to be held December 10 – 13, 2022.
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022
10/3/2022
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 131,000 shares of the company’s common stock to four new employees.
-
MEI Pharma Announces Changes to Board of Directors
9/22/2022
MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Christine A. White, M.D., has decided to retire and thus does not intend to stand for reelection at the Company’s fiscal year 2023 annual meeting of stockholders after a seven-year tenure as chair of the board and 12 years total serving as a director.
-
MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights
9/8/2022
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2022.
-
MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
9/6/2022
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference 2022.
-
MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022
9/1/2022
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2022 fiscal year end financial results after the close of the U.S. financial markets on September 8, 2022.
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2022
9/1/2022
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 64,000 shares of the company’s common stock to two new employees.
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Aug 01, 2022
8/1/2022
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 18,000 shares of the company’s common stock to one new employee.
-
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy
7/18/2022
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. today announced publication of data from the Phase 1b clinical study of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor.
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - July 01, 2022
7/1/2022
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 65,000 shares of the company’s common stock to two new employees.
-
MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer
6/22/2022
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer.
-
According to reports citing “people familiar with the matter,” Kyowa Kirin, a specialty pharma company, could be lining up the sale of $1 billion worth of assets on the international market.
-
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
6/10/2022
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced that data from the zandelisib clinical development program, including the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies, is highlighted in a poster and an oral discussion session at the European Hematology Association 2022 Hybrid Congress.
-
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
6/4/2022
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced data from the ongoing Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies, is highlighted in a poster and oral discussion session at the American Society of Clinical Oncology 2022 Annual Meeting.